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INTRODUCTION
Myocardial infarction (MI) is one of the most common 
causes of death and disability in various societies, especially in 
developed countries, and its complications are one of the main 
health problems in each country, especially in the big cities and 
among middle-aged and adult people [1,2]. Acute MI (AMI), 
which is the most common cause of acute attacks, is often 
caused due to obstructive coronary artery due to a blood clot, 
severe spasm of the arteries or atherosclerosis in the coronary 
arteries. In recent decades, despite of improving public health 
condition in many countries of the world, the incidence of 
cardiovascular diseases has become the most important health 
problem [1-3]. Returning of ST-segment is a good predictor of 
infarct artery patency and preserves myocardial perfusion in 
heart tissue level [4,5]. The successful resolution in ST-segment 
is as an electrocardiographic (ECG) signal of myocardial tissue 
repair which indicates the progression of infarction [6]. If 
the primary percutaneous coronary intervention (PCI) is not 
available, one of the initial treatment of AMI is the prescription 
of thrombolytic medication, which is considered the primary 
and preferred method of lifesaving [2,3]. Among thrombolytic 
medications, streptokinase (SK) due to the opening of the 
blocked artery by thrombosis and reduction of mortality 
without any potential hemorrhagic complications is more 
important [7-9]. Quick start of SK and other thrombolytic 
medications leads to adjacent of ischemic myocardial perfusion 
to the infarct region. The success of thrombolysis in clot lysis 
and creating second reperfusion in saving myocardial ischemic 
and in preserving of myocardial function plays a key role [8]. 
The effect of thrombolytic medications in creating myocardial 
perfusion can be measured by several factors, and angiography 
is considered as a delayed and invasive method in approaching 
the patients who received thrombolytic medications.
Early hours after administration of thrombolytic medication, 
some clinical criteria including clinical response of pain 
reduction of angina after SK, ST-segment resolution, and rapid 
increase in cardiac enzyme creatine kinase-MB (CKMB) are 
predictable [10-12]. Some studies have shown that metabolic 
syndrome includes abdominal obesity and some metabolic 
disorders such as diabetes, hypertension, insulin resistance, and 
dyslipidemia which can put the patients at risk of cardiovascular 
disease and these factors affect the response to the thrombolytic 
medication [13-15]. Because of the high prevalence of metabolic 
syndrome in patients with MI and also its relationship with 
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ABSTRACT
Introduction: Myocardial infarction (MI) therapy is one of the most common causes of death and health 
issue in the world, especially in developed countries. Thrombolytic administration is a preferred life saver 
method of acute MI if primary angioplasty is not possible. Given that the incidence of MI in patients with 
metabolic syndrome, so evaluation of therapeutic response to streptokinase in this regard is very important. 
Methods: In this descriptive analytical study, 340 acute coronary syndrome patients which have study inclusion 
criteria divided randomly in two groups (with and without metabolic syndrome each with 170 patients) and 
collected data analyzed by statistical methods using SPSS 20. Results: Pain improvement after treatment in the 
group without metabolic syndrome was significantly higher than another group (58.2% vs. 23.4%) (P = 0.001). 
ST-segment resolution at 90 min after treatment in the group without metabolic syndrome significantly higher 
than another group (P = 0.002). Conclusion: Results showed that using of angioplasty is recommended as 
the preferred method instead of thrombolytic treatment in patients with metabolic syndrome suffering from MI.
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coronary artery disease, doing study in this area is necessity. 
According to Meigs et al., the risk of coronary artery disease 
in patients with metabolic syndrome was 34% in men and 
16% in women, and the prevalence of metabolic syndrome in 
patients with coronary artery was 50%. Hence, identifying the 
role of metabolic syndrome in the response to thrombolysis in 
myocardial perfusion is better in the clot lysis process of insulin 
resistance in coronary artery and saving the areas caused by 
ischemic MI [16].
Dehghani et al. investigated the factors such as age, diabetes 
mellitus, low-density lipoprotein (LDL), site of MI, and the 
patient’s delay affecting the response to treatment in patients 
who received SK in AMI [2].
As mentioned above, making quick decisions in choosing the 
type of treatment (angiography or use of thrombolytic therapy) 
is effective in the treatment response and reduction of mortality 
rate in these patients. The aim of this study was to evaluate 
clinical, ECG and laboratory response of reperfusion therapy 
in patients with first AMI.
METHODS
This is a descriptive analytical study that has been conducted 
on 340 randomly selected acute coronary syndrome patients 
which have MI symptoms and candidate for receiving SK during 
2013-2014. Patients divided randomly in two groups with and 
without metabolic syndrome each with 170 patients. In the 
baseline, the ECG was taken from all patients and based on the 
ST-segment elevation (about at least 2 mm in two contiguous 
leads [v1-v6]) the ST elevation MI was confirmed and then 
they received SK.
The first history of patient, primary ECG, and then cardiac 
enzyme tests was performed for all patients. Clinical responses 
of the patients to SK by the average of pain criterion before 
SK injection based on pain visual analog scale (scale 0-10) and 
clinical response of pain after SK (50% improvement in pain 
analog scale) was assessed and in the patients’ echocardiography, 
50% of ST-segment resolution at 90 and 180 min after SK 
injection, compared to the first echocardiography, were 
examined. The amount of enzyme CKMB in baseline, 1st and 
2nd days after SK was recorded. Then, all patients were divided 
randomly in two groups by metabolic syndrome criteria. All 
data collected by interview, register clinical information and 
ECG and blood samples were taken during specified hours and 
entered in a datasheet. The written consent form was taken from 
all patients before the study. Collected data were analyzed using 
statistical methods in SPSS 20.
RESULTS
About 51.5% of all patients were in group with metabolic 
syndrome and 48.5% in another group. In both groups, most 
of the patients were male and the mean age in the group 
without the metabolic syndrome was 59.5 ± 9.8 and in the 
group with the metabolic syndrome was 58.2 ± 10.3. In terms of 
anatomical type, most of MI associated with anterior infarction 
with 42.1% and then related to extensive MI with 39.7% and there 
was not a significant difference between the two groups in terms 
of anatomic MI. In investigated patients, hypertensive with 62.1% 
had the highest prevalence [Figure 1]. The mean score of pain in 
baseline in the group without metabolic syndrome was 159 ± 65.6 
and in a group with metabolic syndrome was 149 ± 52.8 and the 
difference between two groups was not significant.
The mean of pain before SK injection on the basis of pain 
visual analog scale in the group without metabolic syndrome 
was 5.3 ± 2.7, and it was 5.2 ± 2.8 in the group with metabolic 
syndrome, and there was no significant difference. The average 
amount of CKMB enzyme before SK injection was 53.3 ± 4.6 
in the group without metabolic syndrome and 47.4 ± 4.3 in the 
group with metabolic syndrome and no significant differences 
were observed between the two groups. Clinical response to pain 
after SK injection (50% improvement in pain analog scale) in 
group without metabolic syndrome was higher than group with 
metabolic syndrome [Table 1].
ST-segment resolution rate about 50% at 90 min after SK was 
statistically significant between two groups and we can resulted 
that the group without metabolic syndrome responded better to 
the SK medication in terms of the 50% ST-segment resolution 
rate at 90 min [Figure 2]. 50% ST-segment resolution rate 
at 180 min after the SK in the two groups was not statistically 
different in none of MI types. The higher rate of the CKMB 
enzyme was similar between two groups.
DISCUSSION
The results were in favor of improving response to SK 
medication in the group without metabolic syndrome in terms 
of 50% ST-segment resolution rate at 90 min. However, the 
50% ST-segment resolution rate at 180 min after the injection 
of SK in the two groups was not statistically different. In 
terms of the laboratory criteria, the higher rate of the CKMB 
enzyme in the 1st day compared to the 2nd day after SK was 
examined and the difference was not statistically significant 
between two groups.
Masoomi et al. investigated the thrombolytic effect of SK 
injection and evaluation of ST-segment in patients suffering MI 
Figure 1: Frequency of diseases in myocardial infarction patients
Zamani, et al.: Evaluation clinical, electrocardiographic and laboratory
J Exp Integr Med ● 2017 ● Vol 7 ● Issue 1  3 
with diabetic and nondiabetic histories and they showed that the 
returning of ST-segment resolution at 180 min after SK was lower 
in diabetic patients compared with nondiabetic patients [17]. 
Khan et al. in a similar study examined the therapeutic effects of 
SK in diabetic patients compared with nondiabetic patients with 
first MI attack and concluded that patients with diabetes have 
worse results in ST-segment resolution compared to nondiabetic 
patients [18]. In this study, the difference between the ST-
segment resolution rate of the patients without metabolic 
syndrome and the ST-segment resolution rate of the patients 
with metabolic syndrome was observed at 90 min, and this 
difference was resolved at 180 min. Furthermore, our cases 
had slightly overlap with the above-mentioned study samples, 
and it is true that diabetes is one of the criteria for metabolic 
syndrome but diabetic individuals, only 30% of our samples, 
existed in both study groups.
Dehghani et al. showed that there is a significant relationship 
between age, history of diabetes mellitus, LDL, site of MI, the 
patient delay and the effect of SK while in this study gender, 
risk factors of blood pressure, smoking, ischemic heart disease, 
the time of MI, and type of SK have been ineffective in response 
to SK medication.
They also concluded that patients with acute MI under the age 
of 30 years and >80 years, with diabetes, LDL over 100 mg/pd, 
a large anterior MI, new left ventricular branch block or delay 
more than 12 h did not have appropriate respond to SK 
medication and it is probable that early invasive approach 
would be more effective than thrombotic therapy [2]. Our 
study had little overlap with Dehghani et al. and Zeymer 
et al. investigated the validity of ST-segment resolution as a 
non-invasive indicator for opening of the coronary artery and 
concluded that the location of myocardial infarcts effects 
on ST-segment resolution ate of in treatment with SK [19]. 
Furthermore, Guzman et al. in a study compared the ST-
segment resolution rate in the anterior ST elevation MI 
and posterior myocardium wall after treatment with SK and 
concluded that returning of ST-segment after 2nd day of the 
injection of SK was lower in anterior MI that is mostly caused 
by the lack of unblocking the veins due to a lack of activity, 
larger infarct size and weaker systolic function [20].
As we mentioned in our study, 50% ST-segment resolution 
rate in 90 min after SK injection was a statistically significant 
difference between the two groups which represents 50% ST-
segment resolution rates were not equal in the two groups in 
90 min after the injection of SK. According to the results, the 
group without metabolic syndrome responded better to the 
SK medication in terms of 50% ST-segment resolution rate 
in 90 min. However, there was not any significant difference 
between none of the MI types and 50% ST-segment resolution 
rate in 90 min.
CONCLUSION
The results showed that ST-segment resolution can be used as an 
efficient measure, like angina pain, in response to thrombolytic. 
Delay in returning ST-segment elevation in the group with 
metabolic syndrome implies that the response to thrombolytic 
in this group is weaker or slower. If this 90 min delay in returning 
of ST is because of the establishment delay of perfusion, it can 
have a negative impact on the survival of the group. According 
to the results of this study, it is suggested that, if possible, 
primary PCI, be used as the preferred method in patients with 
metabolic syndrome who suffer from MI.
Also further studies have been conducted on the impact each 
of the components of metabolic syndrome separately.
Figure 2: 50% resolution percent in ST-segment in 90 min after 
streptokinase injection
Table 1: Clinical responses to pain and ST‑segment resolution rate in two groups
Group Percentage P value OR CI
Clinical response to pain after streptokinase injection (50% recovery in pain analog scale)
With metabolic syndrome 23.4 0.001* 0.22 0.14‑0.35
Without metabolic syndrome 58.2
50% resolution ST‑segment in 90 min after SK injection
With metabolic syndrome 40.6 0.002* 0.49 0.32‑0.76
Without metabolic syndrome 58.2
50% resolution ST‑segment in 180 min after SK injection
With metabolic syndrome 67.4 0.072 0.64 0.4‑1.03
Without metabolic syndrome 76.4
Rate of CKMB enzyme in 1st day compare to 2nd day after SK injection
With metabolic syndrome 44.6 1 1 0.65‑1.52
Without metabolic syndrome 44.8
*Significant at level 0.05. SK: Streptokinase, CKMB: Creatine kinase‑MB
Zamani, et al.: Evaluation clinical, electrocardiographic and laboratory
4 J Exp Integr Med ● 2017 ● Vol 7 ● Issue 1
REFERENCES
1. Honarmand H, Mirblook F. Indexes and risk factors of AMI. J Health 
Care 2009;11:16-24.
2. Dehghani M, Eshraghi A, Shakeri MT, Rastgar AF, Hoshmand GH. 
Influence of various factors on response to streptokinase therapy 
for acute myocardial infarction. Med J Mashhad Univ Med Sci 
2011;54:113-9.
3. Elliott M. ST elevation myocardial infarction: Management. In: 
Braunwald E, Libby P, Bonow R, Zipes DP, editors. Braunwald’s 
Heart Disease. 8th ed. Philadelphia, PA: Elsevier, Saunders; 2007. 
p. 1233-51.
4. Abdel-Salam Z, Wafa S, Kamel S, Nammas W. The modified Selvester 
QRS score: Can we predict successful ST segment resolution in 
patients with myocardial infarction receiving fibrinolytic therapy. 
Cardiol J 2010;17:367-73.
5. Brosh D, Assali AR, Mager A, Kornowski R. Effect of no-reflow during 
percutaneous coronary intervention for acute myocardial infarctionon 
6-month mortality. Am J Cardiol 2007;99:442-5.
6. Uyarel H, Cam N, Okmen E, Kasikcioglu H, Tartan Z, Akgul O, 
et al. Level of selvester QRS score is predictive of ST-segment 
resolution and 30-day outcomes in patients with acute myocardial 
infarction undergoing primary coronary intervention. Am Heart J 
2006;151:1239.e1-7.
7. Philip A. Acute myocardial infarction: Early treatment. Aust Prescr 
1996;19:52-4.
8. Mayer G, Story WE, Seco JE, Nocero MA Jr, Shaskey DJ, Black MA. 
Intravenous streptokinase in acute myocardial infarction. Ann Emerg 
Med 1985;14:410-5.
9. Sikri N, Bardia A. A history of streptokinase use in acute myocardial 
infarction. Tex Heart Inst J 2007;34:318-27.
10. Ghaffari S, Kazemi B, Golzari IG. Efficacy of a new accelerated 
streptokinase regime in acute myocardial infarction: A double blind 
randomized clinical trial. Cardiovasc Ther 2013;31:53-9.
11. Andrews J, Straznicky IT, French JK, Green CL, Maas AC, Lund M, 
et al. ST-segment recovery adds to the assessment of TIMI 2 and 
3 flow in predicting infarct wall motion after thrombolytic therapy. 
Circulation 2000;101:2138-43.
12. Bogaty P, Buller CE, Dorian P, O’Neill BJ, Armstrong PW; Canadian 
cardiovascular society working group. Applying the new STEMI 
guidelines: 1. Reperfusion in acute ST-segment elevation myocardial 
infarction. CMAJ 2004;171:1039-41.
13. Scuteri A, Najjar SS, Morrell CH, Lakatta EG; Cardiovascular Health 
Study. The metabolic syndrome in older individuals: Prevalence and 
prediction of cardiovascular events: The cardiovascular health study. 
Diabetes Care 2005;28:882-7.
14. Parker B, Bruce I. SLE and metabolic syndrome. Lupus 
2013;22:1259-66.
15. Lee Y, Lim YH, Shin JH, Park J, Shin J, Kim KS. The impact of 
metabolic syndrome on clinical outcomes after everolimus-eluting 
stent implantation. Am J Cardiol 2015;116:717-24.
16. Meigs JB, Wilson PW, Nathan DM, D’Agostino RB Sr, Williams K, 
Haffner SM. Prevalence and characteristics of the metabolic 
syndrome in the San Antonio Heart and framingham offspring studies. 
Diabetes 2003;52:2160-7.
17. Masoomi M, Samadi S, Sheikhvatan M. Thrombolytic effect of 
streptokinase infusion assessed by ST-segment resolution between 
diabetic and non-diabetic myocardial infarction patients. Cardiol J 
2012;19:168-73.
18. Khan MA, Khawaja MN, Hakeem F. Predicting clinical outcome in 
diabetics vs. Non diabetics with acute myocardial infarction after 
thrombolysis, using ECG as a tool. J Pak Med Assoc 2011;61:1032-7.
19. Zeymer U, Neuhaus KL, Tebbe U, Vogt A. Influence of infarct 
location on the prognostic impact of thrombolysis in myocardial 
infarction (TIMI) perfusion grade of the infarct-related artery after 
thrombolysis for acute myocardial infarction. J Clin Basic Cardiol 
2000;3:43-5.
20. Guzman E, Khan IA, Rahmatullah SI, Verghese C, Yi KS, Niarchos AP, 
et al. Resolution of ST-segment elevation after streptokinase therapy 
in anterior versus inferior wall myocardial infarction. Clin Cardiol 
2000;23:490-4.
© EJManager. This is an open access article licensed under the terms 
of the Creative Commons Attribution Non-Commercial License (http://
creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-
commercial use, distribution and reproduction in any medium, provided the 
work is properly cited.
Source of Support: Nil, Conflict of Interest: None declared.
